# Collegium Pharmaceutical

Type: Company (COLL)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/collegium-pharmaceutical
Canonical HTML page: https://getbiobrief.com/entity/collegium-pharmaceutical

## Recent coverage (2 stories)

### COLL Q2 EPS Beats by $0.20; Revenue Up 6.3% to $199.88M
2026-08-09 18:28:47 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Collegium Pharmaceutical's earnings beat of $0.20 per share, reaching $1.92 on $199.88M revenue, highlights its commercial success in the abuse-deterrent opioid space, a key sector for the biopharma industry.
Full story: https://getbiobrief.com/story/collegium-pharma-q2-2026-earnings-bio

### Wave Life Sciences and Collegium FY2025 Results Signal RNA and Pain Pivot
2026-02-26 14:28:36 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences and Collegium Pharmaceutical reported full-year 2025 results, highlighting a transformative period for RNA editing and commercial pain management. Wave's clinical progress in AATD and DMD remains a primary valuation driver, while Collegium continues to optimize its specialized portfolio through strategic acquisitions.
Full story: https://getbiobrief.com/story/wave-life-sciences-collegium-fy2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.